Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors

Cancer Science

Volumn 103, Issue 11, 2012, Pages 1994-2001

  Saijo, Ken ^a   Katoh, Tadashi ^b   Shimodaira, Hideki ^a   Oda, Akifumi ^c   Takahashi, Ohgi ^c   Ishioka, Chikashi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Department of Chemical Pharmaceutical Sciences   (Japan)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ABC TRANSPORTER; FK A 1; FK A 2; FK A 3; FK A 4; FK A 5; FK A 6; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; ROMIDEPSIN; SPIRUCHOSTATIN A; SPIRUCHOSTATIN B; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME INHIBITION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SACCHAROMYCES CEREVISIAE; WESTERN BLOTTING;

APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION;

EID: 84868207385     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12002     Document Type: Article

References (28)

1. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998; 67: 481-507.
2. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7.
3. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
4. Ikenoue T, Kanai F, Hikiba Y et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65: 4562-7.
5. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 1998; 273: 13375-8.
6. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133: 403-14.
7. Kong D, Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem 2009; 16: 2839-54.
8. Barberis A, Gunde T, Berset C, Audetat S, Luthi U. Yeast as a screening tool. Drug Discovery Today: Technologies 2005; 2: 187-92.
9. Cid V, Rodríguez-Escudero I, Andrés-Pons A et al. Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast. Oncogene 2008; 27: 5431-42.
10. Rodríguez-Escudero I, Roelants FM, Thorner J, Nombela C, Molina M, Cid VJ. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Biochem J 2005; 390: 613-23.
11. Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011; 20: 1151-8.
12. Xu W, Parmigiani R, Marks P. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-52.
13. Sikorski RS, Hieter P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 1989; 122: 19-27.
14. Alani E, Cao L, Kleckner N. A method for gene disruption that allows repeated use of USR3 selection in the construction of multiply disrupted yeast strains. Genetics 1987; 116: 541-5.
15. Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62: 4916-21.
16. Rogers B, Decottignies A, Kolaczkowski M, Carvajal E, Balzi E, Goffeau A. The pleitropic drug ABC transporters from Saccharomyces cerevisiae. J Mol Microbiol Biotechnol 2001; 3: 207-14.
17. Walker EH, Pacold ME, Perisic O et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000; 6: 909-19.
18. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62: 6141-5.
19. Ropero S, Fraga MF, Ballestar E et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006; 38: 566-9.
20. Hanigan CL, van Engeland M, De Bruine AP et al. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 2008; 135: 1654-64.
21. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000; 97: 10014-9.
22. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998; 241: 126-33.
23. Hartlapp I, Pallasch C, Weibert G, Kemkers A, Hummel M, Re D. Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines. Leuk Res 2009; 33: 929-36.
24. Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T. Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun 2009; 379: 104-9.
25. Reagan-Shaw S, Ahmad N. RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. Cancer Res 2006; 66: 1062-9.
26. Kodani M, Igishi T, Matsumoto S et al. Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells. Oncol Rep 2005; 13: 477-83.
27. Wozniak MB, Villuendas R, Bischoff JR et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 2010; 95: 613-21.
28. Narita K, Kikuchi T, Watanabe K et al. Total synthesis of the bicyclic depsipeptide HDAC inhibitors Spiruchostatins A and B, 5"-epi-Spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity. Chem Eur J 2009; 15: 11174-86.